We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+1.5%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.24B
AUM Growth
-$1.73B
Cap. Flow
-$1.75B
Cap. Flow %
-141.12%
Top 10 Hldgs %
32.38%
Holding
322
New
31
Increased
40
Reduced
64
Closed
112

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$36.4M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$12.7M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$11.6M
4
CGEM icon
Cullinan Oncology
CGEM
+$9.06M
5
ALEC icon
Alector
ALEC
+$7.87M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$24M
2
CRIS icon
Curis
CRIS
+$13.8M
3
NBP
NovaBridge Biosciences American Depositary Shares
NBP
+$13.5M
4
PRTA icon
Prothena Corp
PRTA
+$11M
5
TVRD
Tvardi Therapeutics
TVRD
+$9.32M

Sector Composition

Rank Sector Weight
1 Healthcare 43.58%
2 Technology 0.24%
3 Consumer Staples 0.11%
4 Financials 0.06%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTGN icon
101
VistaGen Therapeutics
VTGN
$9.98M
$2.89M 0.23%
30,552
-65,646
-68% -$4.86M
ASND icon
102
Ascendis Pharma A/S
ASND
$16.5B
$2.87M 0.23%
21,825
-40,265
-65% -$5.37M
WHWK
103
Whitehawk Therapeutics
WHWK
$181M
$2.83M 0.23%
111,740
-65,000
-37% -$1.48M
WGS icon
104
GeneDx Holdings
WGS
$1.89B
$2.8M 0.23%
+6,061
New +$2.6M
ELDN icon
105
Eledon Pharmaceuticals
ELDN
$255M
$2.77M 0.22%
350,000
+100,000
+40% +$943K
IRON icon
106
Disc Medicine
IRON
$2.81B
$2.76M 0.22%
14,215
-8,598
-38% -$2.83M
ALLK
107
DELISTED
Allakos
ALLK
$2.71M 0.22%
31,700
– –
ALPN
108
DELISTED
Alpine Immune Sciences Inc
ALPN
$2.7M 0.22%
300,454
-4,285
-1% -$46.6K
HEPA
109
DELISTED
Hepion Pharmaceuticals
HEPA
$2.7M 0.22%
+1,365
New +$2.5M
SVRA icon
110
Savara
SVRA
$1.08B
$2.7M 0.22%
1,586,737
-127,629
-7% -$230K
IMTX icon
111
Immatics
IMTX
$1.23B
$2.61M 0.21%
225,138
-30,000
-12% -$352K
ALLO icon
112
CALL
Allogene Therapeutics
ALLO
$625M
$2.61M 0.21%
100,000
-16,600
-14% -$473K
CVM icon
113
CALL
CEL-SCI Corp
CVM
$19.9M
$2.6M 0.21%
10,000
+6,437
+181% +$3.98M
INMB icon
114
INmune Bio
INMB
$44.9M
$2.58M 0.21%
146,883
-86,693
-37% -$1.17M
KA
115
DELISTED
Kineta, Inc. Common Stock
KA
$2.56M 0.21%
31,353
– –
LQDA icon
116
Liquidia Corp
LQDA
$7.72B
$2.55M 0.21%
890,435
-60,965
-6% -$169K
GYRE icon
117
Gyre Therapeutics
GYRE
$629M
$2.52M 0.2%
77,493
– –
STRO icon
118
Sutro Biopharma
STRO
$386M
$2.52M 0.2%
13,536
– –
SLDB icon
119
Solid Biosciences
SLDB
$792M
$2.47M 0.2%
45,045
+43,471
+2,762% +$2.87M
CYTK icon
120
Cytokinetics
CYTK
$10.6B
$2.39M 0.19%
120,895
-6,105
-5% -$143K
KALV
121
DELISTED
KalVista Pharmaceuticals
KALV
$2.32M 0.19%
96,965
-200,000
-67% -$5.23M
MDGL icon
122
Madrigal Pharmaceuticals
MDGL
$12.6B
$2.3M 0.19%
23,654
– –
ICAD
123
DELISTED
iCAD Inc
ICAD
$2.22M 0.18%
128,137
-89,500
-41% -$1.57M
ZGNX
124
DELISTED
Zogenix, Inc.
ZGNX
$2.14M 0.17%
124,091
– –
BCEL
125
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$2.13M 0.17%
+250,000
New +$2.56M
3 4
5
6 7

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q2 2021 Portfolio in Review

As of Q2 2021, Ikarian Capital held 322 positions worth $1.24B, down 58% from $2.97B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Ikarian Capital withdrew a net $1.75B in Q2 2021, closing 112 positions and reducing 64 holdings. Its most notable exit was Curis, an estimated $13.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, up from 22% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Ikarian Capital opened a new position in ChemoCentryx, Inc. worth $6.31M.

  • Ikarian Capital's largest Q2 2021 buy was ChemoCentryx, Inc.: 471,376 shares worth $6.31M.
  • Ikarian Capital added most to Biogen in Q2 2021, an estimated $36.4M increase.
  • Ikarian Capital's biggest Q2 2021 reduction was Eli Lilly, cutting an estimated $24M.
  • Ikarian Capital fully exited Curis in Q2 2021, selling an estimated $13.8M.
  • Ikarian Capital's ten largest holdings make up 32% of its $1.24B portfolio in Q2 2021.
  • Ikarian Capital opened 31 new positions and closed 112 in Q2 2021.
  • Ikarian Capital's portfolio value fell 58% quarter-over-quarter to $1.24B.

Based on Ikarian Capital's 13F filing for Q2 2021, filed 16 Aug 2021.